NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study of Early Secukinumab Treatment in Moderate to Severe Hidradenitis Suppurativa Patients

Not Yet RecruitingN/A

Sponsor: Novartis Pharmaceuticals

Conditions: Hidradenitis Suppurativa

The aim of this study is to evaluate the effectiveness of early treatment with secukinumab in patients with moderate-to-severe hidradenitis suppurativa (HS) and assess its impact on disease progression using data from multiple European data sources. All data will be sourced from existing non-interventional study primary data collection, registries, and hospital cohorts that captured information collected in routine clinical practice, prior to and independent of this study.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion criteria:

* Patients with a documented diagnosis of HS (e.g., International Classification of Diseases, 10th Revision \[ICD-10\] code L73.2);
* Age ≥18 years at index date;
* Moderate-to-severe HS as per label;
* Initiation of secukinumab treatment on or after the first HS diagnosis date;
* And at least one follow-up assessment at 6 or 12 months after index date.

Exclusion criteria:

* Patients who had major HS-related surgery (Skin-tissue-sparing Excision with Electrosurgical Peeling \[STEEP\] or wide excision) in the 12 months prior to index date;
* Patients participating in interventional clinical trials at index date.

Other protocol-defined inclusion/exclusion criteria may apply.